NCT04211272View on ClinicalTrials.gov

A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

April 19, 2021

Study Completion Date

April 19, 2021

Conditions
Healthy
Interventions
DRUG

Macitentan

Macitentan will be administrated as film-coated tablet in Part A and Part B.

DRUG

Sildenafil

Sildenafil will be administrated as film-coated tablet in Part A.

DRUG

Riociguat

Riociguat will be administrated as film-coated tablet in Part A.

DRUG

Rosuvastatin

Rosuvastatin will be administrated as film-coated tablet in Part B.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY

NCT04211272 - A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants | Biotech Hunter | Biotech Hunter